Literature DB >> 1928527

Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus.

L Solomon1, R Frank, D Vlahov, J Astemborski.   

Abstract

BACKGROUND: Intravenous drug users (IVDUs) with human immunodeficiency virus (HIV) infection and AIDS often have no health insurance or rely on public programs to finance their health care. We examined the independent contributions of HIV serostatus, clinical symptoms, CD4 cell counts, and health insurance to utilization of health services among 1881 intravenous drug users in Baltimore, Maryland.
METHODS: Participants in an ongoing natural history study of HIV were informed of HIV serostatus and seropositives were informed of CD4 cell counts; 6 months later, participants were administered a questionnaire concerning self-reported use of health services, insurance coverage, and HIV-related symptoms.
RESULTS: Of 1881 participants, 67% had health insurance (including Medicaid), 48% had at least one outpatient visit, and 12% had at least one inpatient visit within the prior 6 months. The proportion of the study population that was HIV-1 seropositive was 32%. In multivariate analysis, the single most important predictor of health care utilization was the presence of two or more HIV-related clinical symptoms. HIV positive serostatus alone or known low CD4 counts were not significantly associated with use of health care services.
CONCLUSIONS: These data suggest that HIV seropositive IVDUs are not receiving recommended preventive care. Additional efforts will be needed to ensure that HIV-seropositive drug users participate in currently recommended protocols for early treatment of asymptomatic HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928527      PMCID: PMC1405342          DOI: 10.2105/ajph.81.10.1285

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  The 'Medicaidization' of AIDS. Trends in the financing of HIV-related medical care.

Authors:  J Green; P S Arno
Journal:  JAMA       Date:  1990-09-12       Impact factor: 56.272

2.  Financing the struggle against AIDS.

Authors:  J K Iglehart
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

3.  The economic impact of AIDS in the United States.

Authors:  A A Scitovsky
Journal:  Health Aff (Millwood)       Date:  1988       Impact factor: 6.301

4.  Epidemiology of HIV infection and AIDS in the United States.

Authors:  J W Curran; H W Jaffe; A M Hardy; W M Morgan; R M Selik; T J Dondero
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

5.  Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood.

Authors:  R A Hoffman; P C Kung; W P Hansen; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

6.  Patterns of utilization. The patient perspective.

Authors:  B S Hulka; J R Wheat
Journal:  Med Care       Date:  1985-05       Impact factor: 2.983

7.  AIDS statistics and the risk for minorities.

Authors:  R Bakeman; J R Lumb; D W Smith
Journal:  AIDS Res       Date:  1986

8.  Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users.

Authors:  D C Des Jarlais; S R Friedman; W Hopkins
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

9.  Some interim results from a controlled trial of cost sharing in health insurance.

Authors:  J P Newhouse; W G Manning; C N Morris; L L Orr; N Duan; E B Keeler; A Leibowitz; K H Marquis; M S Marquis; C E Phelps; R H Brook
Journal:  N Engl J Med       Date:  1981-12-17       Impact factor: 91.245

Review 10.  Prevalence of HIV infection among intravenous drug users in the United States.

Authors:  R A Hahn; I M Onorato; T S Jones; J Dougherty
Journal:  JAMA       Date:  1989-05-12       Impact factor: 56.272

View more
  25 in total

Review 1.  Urbanization, urbanicity, and health.

Authors:  David Vlahov; Sandro Galea
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

Review 2.  Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration.

Authors:  Sandro Galea; David Vlahov
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

3.  Health care utilization among drug-using and non-drug-using women.

Authors:  Claire E Sterk; Katherine P Theall; Kirk W Elifson
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

4.  Survival patterns among HIV+ individuals based on health care utilization.

Authors:  K J Welch; A Morse
Journal:  J Natl Med Assoc       Date:  2001-06       Impact factor: 1.798

5.  Delayed access to HIV diagnosis and care: Special concerns for the Southern United States.

Authors:  Christopher S Krawczyk; Ellen Funkhouser; J Michael Kilby; Sten H Vermund
Journal:  AIDS Care       Date:  2006

6.  Does self-report data on HIV primary care utilization agree with medical record data for socially marginalized populations in the United States?

Authors:  Nancy L Sohler; Sharon M Coleman; Howard Cabral; Sylvie Naar-King; Carol Tobias; Chinazo O Cunningham
Journal:  AIDS Patient Care STDS       Date:  2009-10       Impact factor: 5.078

7.  Health insurance and utilization in Pneumocystis carinii pneumonia.

Authors:  S Loue; D J Slymen; H Morgenstern; C Whalen
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

8.  Where injecting drug users receive HIV counseling and testing.

Authors:  R O Valdiserri; T S Jones; G R West; C H Campbell; P I Thompson
Journal:  Public Health Rep       Date:  1993 May-Jun       Impact factor: 2.792

9.  Mental illness and length of inpatient stay for medicaid recipients with AIDS.

Authors:  Donald R Hoover; Usha Sambamoorthi; James T Walkup; Stephen Crystal
Journal:  Health Serv Res       Date:  2004-10       Impact factor: 3.402

10.  Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men.

Authors:  C M Lyles; N M Graham; J Astemborski; D Vlahov; J B Margolick; A J Saah; H Farzadegan
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.